BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024
24 mai 2024 08h00 HE
|
BriaCell Therapeutics Corp.
83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS metastasesMedian progression free survival (PFS) of 4.1 months in ADC...
Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises
22 mai 2024 08h30 HE
|
Biodexa Pharmaceuticals PLC
May 22, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises Proceeds Cover Year 1 eRapa Phase 3 Obligations, Unlocking...
Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to Present Positive Phase 2 Study Findings at European Hematology Association (EHA) 2024 in June
20 mai 2024 07h03 HE
|
Wugen
Wugen Announces RMAT and PRIME Designations for WU-CART-007 and Plans to Present Positive Phase 2 Study Findings at EHA 2024
BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
17 mai 2024 16h33 HE
|
BriaCell Therapeutics Corp.
PHILADELPHIA and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
16 mai 2024 07h00 HE
|
Tourmaline Bio, Inc.
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering
15 mai 2024 08h00 HE
|
BriaCell Therapeutics Corp.
PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
[Latest] Global Breast Cancer Therapeutics Market Size/Share Worth USD 66.1 Billion by 2033 at a 6.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
06 mai 2024 08h30 HE
|
Custom Market Insights
Austin, TX, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Breast Cancer Therapeutics Market Size, Trends and Insights By Type of Therapy...
[Latest] Global Cancer Cachexia Market Size/Share Worth USD 5.1 Billion by 2033 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
03 mai 2024 04h30 HE
|
Custom Market Insights
Austin, TX, USA, May 03, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Cancer Cachexia Market Size, Trends and Insights By Therapeutics (Progestogen,...
Aanastra Inc to Showcase its Peptide-RNA Therapeutics Technology in Multiple Presentations at the American Society for Gene and Cell Therapies (ASGCT) Annual Meeting 2024
02 mai 2024 06h30 HE
|
Aanastra Inc
Aanastra showcases its peptide-RNA therapeutics targeting p53, KRAS and BRCA-1 driven cancers, hemophilia A and PCSK9 for hypercholestrolemia at ASGCT
[Latest] Global Lipid Nanoparticles Market Size/Share Worth USD 1,899.8 Million by 2033 at a 14.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
02 mai 2024 04h30 HE
|
Custom Market Insights
Austin, TX< USA, May 02, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Lipid Nanoparticles Market Size, Trends and Insights By Type (Nano-Structured...